Attorneys Jonathan Bachand and William Adams co-authored “What Celgene Corp. v. Peter Means For Biosimilar Developers,” which was published on the Biosimilar Development website.
Excerpt: A recent decision by the U.S. Court of Appeals for the Federal Circuit has indicated that pharmaceutical makers with patent protection are unlikely to receive any compensation from the government for the loss of their patents during inter partes review (IPR) decisions by the Patent Trial and Appeal Board (PTAB).
